Abstract
Introduction: Thalidomide, previously banned owing to the issues of teratogenicity is being used and tested for a variety of dermatological and non dermatological conditions. The drug has been approved for the management of erythema nodosum leprosum [ENL] and multiple myeloma [MM]. The drug is commonly known to produce adverse effects like peripheral neuropathy and constipation. Deep vein thrombosis [DVT] is one of the serious adverse effects seen with thalidomide use, especially in malignancies and is relatively uncommon in non cancer settings like ENL.
Method: Here we report a case of DVT occurring after 8 months of use of thalidomide in a young patient of 22 years age suffering from ENL. Result: The case highlights the problems faced in the management of refractory ENL and the treatment of DVT in the setting of multiple drug interactions and financial constraints. Conclusion: New guidelines are required regarding the prophylaxis and management of DVT associated with thalidomide use in non-malignant conditions.Keywords: Hansen's disease, ENL, DVT, thalidomide, pharmacovigilance, azathioprine.
Graphical Abstract
Current Drug Safety
Title:Deep Venous Thrombosis Associated with Thalidomide use in a Case of Steroid Dependent Erythema Nodosum Leprosum-a Management Conundrum
Volume: 12 Issue: 2
Author(s): Upinder Kaur, Sankha Shubhra Chakrabarti, Rohit Singh and Indrajeet Singh Gambhir*
Affiliation:
- Department of General Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi- 221005, UP,India
Keywords: Hansen's disease, ENL, DVT, thalidomide, pharmacovigilance, azathioprine.
Abstract: Introduction: Thalidomide, previously banned owing to the issues of teratogenicity is being used and tested for a variety of dermatological and non dermatological conditions. The drug has been approved for the management of erythema nodosum leprosum [ENL] and multiple myeloma [MM]. The drug is commonly known to produce adverse effects like peripheral neuropathy and constipation. Deep vein thrombosis [DVT] is one of the serious adverse effects seen with thalidomide use, especially in malignancies and is relatively uncommon in non cancer settings like ENL.
Method: Here we report a case of DVT occurring after 8 months of use of thalidomide in a young patient of 22 years age suffering from ENL. Result: The case highlights the problems faced in the management of refractory ENL and the treatment of DVT in the setting of multiple drug interactions and financial constraints. Conclusion: New guidelines are required regarding the prophylaxis and management of DVT associated with thalidomide use in non-malignant conditions.Export Options
About this article
Cite this article as:
Kaur Upinder, Chakrabarti Shubhra Sankha, Singh Rohit and Gambhir Singh Indrajeet*, Deep Venous Thrombosis Associated with Thalidomide use in a Case of Steroid Dependent Erythema Nodosum Leprosum-a Management Conundrum, Current Drug Safety 2017; 12 (2) . https://dx.doi.org/10.2174/1574886312666170518153225
DOI https://dx.doi.org/10.2174/1574886312666170518153225 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Applications for Invasive and Non-invasive Tools in the Era of Contemporary
Percutaneous Coronary Revascularisation
Current Cardiology Reviews The Role of Hypoxia and Platelets in Air Travel-Related Venous Thromboembolism
Current Pharmaceutical Design Cardiovascular Complications in Patients with Klinefelter’s Syndrome
Current Pharmaceutical Design Anticancer Activity of Selenium Nanoparticles <i>In Vitro</i> Studies
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Hypothermia in Brain Injuries and Related Diseases
Recent Patents on Inflammation & Allergy Drug Discovery Development of New Fibrinolytic Agents
Current Pharmaceutical Design Bioresorbable Scaffolds for Atheroregression: Understanding of Transient Scaffolding
Current Cardiology Reviews Modulators of Vascular Sex Hormone Receptors and their Effects in Estrogen-Deficiency States Associated with Menopause
Recent Patents on Cardiovascular Drug Discovery Antiphospholipid Antibody-Mediated Thrombotic Mechanisms in Antiphospholipid Syndrome: Towards Pathophysiology-Based Treatment
Current Pharmaceutical Design Alterations in Homocysteine Metabolism Among Alcohol Dependent Patients - Clinical, Pathobiochemical and Genetic Aspects
Current Drug Abuse Reviews Pharmacometabonomics Technique to Identify Warfarin Response Using Nuclear Magnetic Resonance Spectroscopy
Current Pharmaceutical Biotechnology Lupus Nephritis: A Treatment Update
Current Clinical Pharmacology Novel uses of Imaging in AF Ablation
Recent Patents on Cardiovascular Drug Discovery Heart Valve Lesions In The Antiphospholipid Syndrome
Current Rheumatology Reviews Thrombosis and Nephrotic Syndrome in Children
Current Pediatric Reviews To Bleed or Not to Bleed: That is the Question. The Side Effects of Apixaban
Current Drug Targets Atrial Fibrillation – New Frontiers in Anticoagulation
Cardiovascular & Hematological Disorders-Drug Targets Discovery-Based Strategies for Studying Platelet Function
Mini-Reviews in Medicinal Chemistry Drug Therapies in the Secondary Prevention of Cardiovascular Diseases:Successes, Shortcomings and Future Directions
Current Vascular Pharmacology Treatment of PSA only Recurrence of Prostate Cancer After Prior Local Therapy
Current Pharmaceutical Design